Immunology Archives - Page 6 of 11

Pharmacological treatment of COVID-19: lights and shadows

Francesco Menzella MD, Mirella Biava Msc, Chiara Barbieri MD, Francesco Livrieri MD, Nicola Facciolongo MD

Article Type

Review

Published

19 May 2020

The aim of this review is to explore COVID-19 treatment options and describe the potential benefits or disadvantages of their use in severe cases.

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Sonam Puri MD, Michael Shafique MD

Article Type

Review

Published

13 Jan 2020

This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade in non-small-cell lung cancer (NSCLC).

Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD

Article Type

Corrigendum

Published

18 Dec 2019

The authors wish to make corrections to their article: Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs in Context 2019; 8: 212605. DOI: 10.7573/dic.212605

Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues

Ashutosh M Shukla MD, Aparna Wagle Shukla MD

Article Type

Review

Published

25 Nov 2019

This article reviews the expanding clinical applicability of chloroquine and related drugs includes rheumatological and cardiovascular disorders (CVD), chronic kidney disease (CKD), oncology, and a variety of nonmalarial infections.

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Martina Biggioggero MD, Andrea Becciolini MD, Chiara Crotti MD, Elena Agape MD, Ennio Giulio Favalli MD

Article Type

Review

Published

24 Oct 2019

This narrative review discusses the rationale for JAK inhibition in RA, with a special focus on the role of JAK1 selective blockade and a detailed description of available data from the results of clinical trials on upadacitinib and filgotinib.